NOTCH1 encodes a transmembrane signaling protein that plays key roles in development and neoplasia. Its leukemogenic involvement was first revealed by analysis of t(7;9)(q34;q34.3) in a T-cell acute lymphocytic leukemia (T-ALL) cell line (SUP-T1), which juxtaposes truncated NOTCH1 with TCRB, directing overexpression of N-terminally truncated polypeptides (reviewed in Grabher et al .1 ). Wild-type NOTCH1 is initially cleaved (S1 cleavage) into twin polypeptides: an extracellular N-terminal subunit (NEC) and a transmembrane C-terminal Figure 1 Cytogenetic and molecular breakpoint analysis of t(9;14)(q34;q11). (a) Breakpoint data, clone maps and the genomic structures of NOTCH1, including protein domain schema, and TRAD Note the intra-heterodimerization domain (HD) breakpoints in HD-MAR/HT-1 downstream of the S2 metalloprotease cleavage site, and the cis-HD breakpoint in SUP-T1. (b) Chromosome painting of t(9;14), and (c and d) FISH analyses of NOTCH1 and TRAD, respectively, in HD-MAR 4 and HT-1. 5 TRAD/NOTCH1 breakpoint junction sequences determined by longdistance inverse (LDI)-PCR are shown in (e) and (f), respectively. Nucleotides are shown in red, green and black to indicate TRAD, filler DNA and NOTCH1, respectively, with breakpoints shown as black dots. LDI-PCR was performed as described elsewhere. 6 Primer sequences are given in the Supplementary data. subunit (NTM). Binding of NOTCH ligands to the epidermal growth factor-like repeats region of NEC promotes metalloprotease cleavage of NTM (S2 cleavage) to create membrane-bound NTM n I monomers ( Figure 1a ). These are cleaved in turn (S3 cleavage) at multiple sites within the heterodimerization domain (HD) binding extracellular and transmembrane subunits by the g-secretase (GS) protease complex to release the intracellular domain (ICN1), which forms a ternary complex stimulating effector transcription.
1 ICN1 contains regulator of amino acid metabolism (RAM), ankyrin repeat and transcriptional activation domains, and a C-terminal polypeptide enriched with proline, glutamate, serine and threonine (PEST). Ankyrin and transcriptional activation domains are required for induction of T-ALL in mice.
2 Whereas g-secretase inhibitors (GSi) may prove effective against T-ALL subsets, most T-cell lines are resistant, including SUP-T1. 3 We describe a second NOTCH1 rearrangement, t(9;14)(q34.3;q11.2), in T-ALL cell lines, HD-MAR 4 and HT-1, 5 both highly GSi-sensitive despite overexpressing truncated NOTCH1.
Cytogenetic analysis revealed t(9;14)(q34.3;q11.2) in both HD-MAR and HT-1 cells, with NOTCH1 breakpoints inside fosmid 80019F4 accompanied in HD-MAR cells by deletion of B80 kbp corresponding to NEC (Figures 1a-d Figure S1 A/B). t(9;14) in HD-MAR and HT-1 cells places NOTCH1, truncated inside HD (predicted 5 amino acids trans-of the S2 cleavage site), under transcriptional control of TRAV ( Figure 1a) . The TRAV-40 breakpoint in HD-MAR lies close to the proximal Ed enhancer, whereas that in HT-1 at TRAV-5 lies B600 kbp upstream near a cluster of DNase-I hypersensitive sites known to drive oncogene transcription in T-ALL. Thus, both t(9;14) cell lines carry breakpoints located inside HD, in contrast with that lying upstream (cis-) of HD in t(7;9) SUP-T1 cells. g-Secretase inhibitor treatment effected dose-dependent reductions of cell growth and viability in HD-MAR and HT-1, while sparing SUP-T1 cells (Figure 3a) . The GSi sensitivities of both t(9;14) cell lines significantly exceeded that of T-ALL1, which was described earlier as sensitive. 3 Proliferation arrest in HD-MAR and HT-1 paralleled dose-dependent increases in G0/ G1 arrest after GSi treatments, which evinced progressively weaker responses in TALL-1 and SUP-T1 cells (Figure 3b ). To investigate these differential GSi sensitivities, downregulation of NOTCH1 transcriptional target genes, HES1 and MYC were respectively, measured in HD-MAR (92, 66%), HT-1 (94, 79%) and SUP-T1 (75, 39%) cells. Differential Gsi sensitivities of NOTCH1 effector gene expression thus paralleled both cell survival and cell cycle progression endpoints (Figures 3c and d) , confirming the greater GS-dependence of NOTCH1 signaling in intra-HD breakpoint cells.
Inhibiting cleavage by GS-dependence (GSi) treatment effected the accumulation of four ANK þ species (105-116 kDa) taken as NTM/NTM n I (Figure 3e brackets), and dissipation of B110 kDa TM/RAM þ (ICN1), that is, a picture consistent with interconversion. This result underlines the dependence of TM/RAM expression on GS activity in t(9;14) cells. A fifth truncated B100 kDa NTM/NTM n I accumulated in HT-1 cells (arrow). Immunostaining revealed greater accumulation of Western blots were performed after lysis with 50 ml of RIPA buffer (1 ml aprotinin (1 mg/ml), 5 ml PMSF (20 ng/ml) and 50 ml 2 Â SDS). Antibodies used: NOTCH1 (mN1A; BD Biosciences, San Diego, CA, USA, bTAN-20; Hybridoma Bank, Iowa City, IA, USA and Ab8925; Abcam, Cambridge, UK). Loading was checked using Ponceau dye and anti-human-MSH6 Ab (Santa Cruz Biotechnology, Heidelberg, Germany).
perimembraneous NOTCH1 at the expense of intranuclear forms in HD-MAR than in SUP-T1 (Figure 3f ). Taken together, GSi treatments revealed increased dependence of intra-HD breakpoint cells on GS activity for NOTCH1 expression, signaling and proliferation. The enhanced TM/RAM epitope exposure of both t(9;14) cell lines (Figure 2a bottom) suggests a protein structural basis underlying the reduced dependence of GS cleavage on prior S2 cleavage owing to their adjacent breakpoints. The correlation of GS sensitivity with intra-HD breakpoint placement is consistent with data from a second t(7;9) cell line CUTLL1 with an intra-HD breakpoint, also sensitive to GSi. 7 In T-ALL mutations occur in the F-box protein FBXW7 (alias FBW7, hCdc4), which abrogate its binding to NOTCH1, affecting NOTCH1 longevity and GSi responses. However, analysis of HD-MAR, HT-1 and SUP-T1 cells showed normal sequences around Arg465, Arg 479 and Arg 505 hotspots, discounting a major contribution in modulating GSi sensitivity thereby, refocusing the spotlight on GS cleavage.
All the three molecularly karyotyped t(9;14)(q34;q11) cases report TRAD/NOTCH1 involvement (Gesk et al., 8 this report). All the five age-recorded t(9;14) cases were hitherto described in young adults (Table 1) , whereas all four t(7;9) cases are pediatric (http://atlasgeneticsoncology.org/), raising the question whether different age groups might be targeted. However, only a few piecemeal cases have been described for either translocation and additional mapped examples are required to delineate breakpoints in both t(9;14) and t(7;9) T-ALL and help determine the clinical relationship of the cytogenetic entities.
Our findings highlight the role of intra-HD NOTCH1 breakpoint locations in promoting ligand-independent transcription and translation of GSi-sensitive polypeptides. Hightened GSi sensitivity bestowed by such intra-HD breakpoints may reflect increased molecular exposure near the HD region facilitating NOTCH1 cleavage. Independence from ligandmediated cleavage may serve to promote the 'non-oncogene addiction' of intra-HD breakpoint cells on GS cleavage for NOTCH1 signaling.
In summary, we have characterized a new NOTCH1 alteration, t(9;14)(q34;q11), in T-ALL, which is only the second neoplastic NOTCH1 chromosome rearrangement described hitherto. Our data highlight breakpoints in the peri-HD region in determining GS activity and responses to inhibitor. Cell line models for the entity described here provide singular tools for Figure 3 Responses of t(9;14) cells to g-secretase inhibitors (GSi) treatment .T-ALL cell lines were cultured for 96 h with the indicated concentrations of DAPT or mock-treated with dimethylsulfoxide (DMSO). Cellular proliferation and DNA content were, respectively, measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay (a) and by flow cytometry (b) after staining with propidium iodide. Note GSi hypersensitivities of HD-MAR and HT-1 t(9;14) cells at both endpoints. To analyze the effects of GSi on NOTCH1 signaling, t(9;14) and t(7;9) cells were treated for 16 h with 2 mM DAPT and subsequently analyzed by RQ-PCR to measure expression of HES1 (c) and MYC (d), both shown in black. The DMSO-control was set at 100% (gray). Bars show standard deviations. Again note the greatest HES1/MYC dependence on NOTCH1 signaling in t(9;14) cells. For reverse transcription quantitative (RQ)-PCR, cDNA was synthesized from 5 mg total RNA extracted from 2 Â 10 6 cells with TRIzol (Invitrogen, Karlsruhe, Germany) by random priming in 20 ml using Superscript II (Invitrogen). RQ-PCR used the 7500 Real-Time System (Applied Biosystems, Darmstadt/Germany). Expression of HES1, MYC and the control gene TBP was analyzed using commercial primer sets (Applied Biosystems). To analyse the effects of GSi on NOTCH1 polypeptides, western analysis was performed on HD-MAR and HT-1 cells treated with 2 mM DAPT for the times indicated. Chronic myeloid leukaemia (CML) arises from the formation of the Philadelphia (Ph þ ) chromosome in haematopoietic stem cells. The translated fusion oncoprotein, BCR-ABL (p210 BCRÀABL ), is a constitutively active tyrosine kinase (TK), which activates multiple proliferative and anti-apoptotic signalling pathways, causing deregulated cell growth. 1 Despite impressive rates of complete cytogenetic response (CCyR) in the majority of patients treated with the targeted TK inhibitor (TKI), imatinib mesylate (IM; Glivec, Novartis, Basle, Switzerland), 2 few patients achieve sustained molecular remission and a significant proportion develops resistance to IM. 3 The presence of preexisting or acquired BCR-ABL kinase domain mutations, which decrease IM binding, 3 and the innate insensitivity of primitive quiescent CML stem cells to IM 4 are two contributing resistance mechanisms. Consequently, many strategies have been investigated to overcome IM resistance, including the development of second-generation TKIs, nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, Bristol-Myers Squibb, Princeton, NJ, USA), although these remain ineffective against the T315I mutation.
In search of alternative strategies for the elimination of Ph þ cells, Vigneri and Wang 5 showed an intriguing strategy of tricking BCR-ABL þ cells into committing cell death. This mechanism was based on the observation that on treatment with IM, inactive BCR-ABL translocates into the cell nucleus. Entrapment of BCR-ABL there, coupled with re-activation of its TK activity, reversed its role to that of an activator of apoptosis. On the basis of the mounting evidence that BCR-ABL þ stem cells are not eliminated by novel targeted therapies, such as IM and the second-generation TKIs, we investigated whether combination treatment of IM, with the nuclear export inhibitor leptomycin B (LMB Calbiochem), could drive CML CD34 þ cells into apoptosis.
Our initial experiments, over a period of 16 days, on the effects of IM, LMB and the combination of these drugs on the Ph þ cell line K562, showed that treatment with either drug alone for the first 72 h was at least cytostatic. However, 5-8 days after drug washout, cells were able to recover, an effect not seen with the drug combination,in which irreversible growth 
